Aug 2026· Virologica Sinica· 0 citations· 82 references
Medicine
TL;DR
Current knowledge of how RNA-centered mechanisms regulate SFTSV RNA fate, viral replication, host adaptation, immune antagonism, and cross-host transmission is summarized.
Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne pathogen that causes substantial morbidity and high case fatality in severe cases, representing a major public health concern in East Asia. Although protein-mediated mechanisms of SFTSV replication and immune evasion have been extensively studied, accumulating evidence indicates that viral infection is also influenced by RNA-centered regulatory processes. These processes include viral RNA transcription and replication, epitranscriptomic modification, host RNA-binding proteins, RNA interference-related pathways, small RNA responses, and NSs-driven inclusion bodies. Current evidence is strongest for L protein-mediated viral RNA transcription and replication, m6A-related regulation of viral RNA stability and translation, selected host RNA-binding proteins involved in viral RNA metabolism, and NSs-mediated antagonism of AGO2-dependent RNA interference and antiviral signaling. In contrast, the direct role of m6A in innate immune sensing, the functional significance of virus-derived microRNA-like small RNAs, and the physical protection of viral RNA within NSs-driven condensates remain incompletely established. In this review, we summarize current knowledge of how RNA-centered mechanisms regulate SFTSV RNA fate, viral replication, host adaptation, immune antagonism, and cross-host transmission. We further discuss their potential implications for biomarker discovery and antiviral development, while emphasizing the uneven strength of evidence and the mechanistic and translational barriers that remain. An evidence-stratified RNA-centered framework may help prioritize future studies and guide the rational exploration of RNA-based diagnostic and therapeutic strategies for SFTSV infection.
This framework separates demonstrated mechanisms from inferred biological consequences and identifies the validation required before accessory-ORF biology can inform host-range assessment, therapeutic development, sequence surveillance, or rational attenuation of MERS-CoV infection.
Chun-Hua Wang, Xu-Hang Li, Yi Jiang et al.· Frontiers in Immunology· 0 citations
The miRNA-virus axis is reinterprets as a dynamic regulatory network and provides a translational framework for the development of next-generation antiviral therapeutics.
Dakshina M. Nair, L. Vajravelu, Rahul Harikumar Lathakumari et al.· Microbial Pathogenesis· 0 citations
It is reported that SESN1 acts as a critical negative regulator of mitochondrial antiviral signaling protein (MAVS), a central hub protein in RNA-triggered innate immune response, by potentiating MAVS autophagic degradation to repress innate immune response.
Qiang-Hui Liu, Peiran Chen, Chun-Yan He et al.· Proceedings of the National...· 0 citations
The existing mechanistic knowledge about the PTBP1 functions during viral infection is described and the possibility of PTBP1 being used as a host-directed antiviral drug target despite the hurdles in doing so considering its multifunctionality as an essential cellular RNA-binding protein is explored.
This work discusses viral-derived circRNAs, highlighting emerging evidence that HIV-1 encodes functional circRNA isoforms capable of modulating viral replication and transcription, and reviews synthetic circRNA-based approaches that exploit key viral RNA–protein interactions as potential antiviral tools.
Gabriela Berger, Y. G. Chen· RNA Biology· 0 citations
A METTL3-directed Proteolysis Targeting Chimera (PROTAC) phenocopied STM2457, producing IFN-independent antiviral activity and ruling out off-target inhibition of viral RNA methyltransferases as a plausible explanation are defined.
Ikshitaa Dinesh, Joaquim M. G. D. Fonseca, Denise Ohnezeit et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.